I am so confused by the numbers now but I have not invested the required time and I thank everyone for this discussion as we sit in this "double blinded guessing game".

I have a question and I am reluctant to ask it because I am sure it has been answered. In the CEO & Investor Conference in NYC on Feb 12, 13 on page 16 it shows the annual rate of MACE events among people with ACS and diabetes mellitus is 9.5% and this is stated as the BoM target. We don't know much about this number. Were these people on SOC? Do they match BoM?

BDAZ did a follow up with Mr Paradis regarding the combined MACE levels in the BoM trial at this stage and the number is 8 in 100 patients hours (I probably mis stated this). Anyway that number looks like 8%. If this is correctly stated then my question is can the 8% be compared to the 9.5% as per page 16 of NYC?

Congrats to RVX re the 6th DSMB report. Great news!

Finally, BDAZ's posts about ABBVie I think is very significant particularly when they have ABBV-744, a BD-2 selective BET inhibitor in a cancer trial for mCRPC and AML. So a drug possibly like apabetalone (being tested on MACE) is going into trials for a couple of cancers and as Don told us cancer trials move fast. Quick success on mCRPC could get them to market soon. Once on the market they could apply for other indications like MACE. The big boys are now in the BD-2 game. As BDAZ says they'll need to pass phases 1,2 and 3 MACE trials and that gives apabetalone an advantage. But they won''t have any financing problems.

GLTA

Toinv